medica glp-1 coverage glp 1 Medicaid of and Spending on GLP-1s Recent Trends in Use – Pennsylvania Medicaid Covers Newer Weight

Bravo-Veyrat S, Hopfgartner G

Tirzepatide, a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), may indirectly affect menstrual cycles in some women

FM 2.0 Functional Alternatives & Natural GLP-1 Support It integrates Functional Medicine 2.0 (FM 2.0) principles precision, resilience, and system integration while preserving clarity, warmth, and evidence-based credibility

This review covers pharmacologic alternatives for treating obesity, with emphasis on the benefits associated with the novel use of glucagon-like peptide-1 (GLP-1) agonists that act on satiety receptors